RxDoctor Payments DataLook up a doctor →

Bradley Hardy, DO

Family Medicine · Tulsa, OKNPI 1912240052

Payments from drug & device makers

$16,687in general payments, 2019–2025

Across 1,109 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • GSK$2K
  • Lilly USA, LLC$2K
  • AstraZeneca$2K
  • Johnson & Johnson$997
  • plus $7K from 45 others

What the payments were for

  • Food & beverage$16,670100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,687 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$51,633
Medicare patients
191
Services billed
1,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$68,248
OzempicSemaglutide53$64,762
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$55,278
XareltoRivaroxaban32$51,073
JardianceEmpagliflozin28$34,986
MounjaroTirzepatide23$28,142
JanuviaSitagliptin Phosphate18$21,183
TrulicityDulaglutide20$20,137
MyrbetriqMirabegron29$18,815
FarxigaDapagliflozin Propanediol19$16,289
Tresiba Flextouch U-200Insulin Degludec21$11,690
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,080
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$9,999
Atorvastatin Calcium321$8,671
Rosuvastatin Calcium152$4,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,652$69,853107 claims
PfizerEliquis$982$68,24871 claims
Novo NordiskOzempic$2,027$64,76253 claims
Johnson & JohnsonXarelto$997$51,07332 claims
Lilly USA, LLCMounjaro, Trulicity$1,560$48,27843 claims
Boehringer IngelheimJardiance$823$34,98628 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,557$27,36936 claims
MerckJanuvia$547$21,18318 claims
Astellas Pharma US IncMyrbetriq$255$18,81529 claims
AbbVieSynthroid$1,762$2,75922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →